Verrica Pharmaceuticals Inc. (VRCA) Q2 FY26 Earnings Call

$5.1 million U.S. net WICANT revenue rose 18.7% sequentially, while dispensed units increased 28% to 19,626.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-30
Length37 minutes
EPS$-0.54
Revenue$5.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All VRCA earnings ยท Back to VRCA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.